158 related articles for article (PubMed ID: 22215144)
1. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
Yan X; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):141-6. PubMed ID: 22215144
[TBL] [Abstract][Full Text] [Related]
2. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
Yan X; Ruixo JJP; Krzyzanski W
AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
[TBL] [Abstract][Full Text] [Related]
3. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
4. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
5. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of target-mediated drug disposition.
Peletier LA; Gabrielsson J
Eur J Pharm Sci; 2009 Dec; 38(5):445-64. PubMed ID: 19786099
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.
Peletier LA; Gabrielsson J
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):429-51. PubMed ID: 22851162
[TBL] [Abstract][Full Text] [Related]
8. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
Marathe A; Krzyzanski W; Mager DE
J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483
[TBL] [Abstract][Full Text] [Related]
9. Target-mediated drug disposition model for drugs with Nā>ā2 binding sites that bind to a target with one binding site.
Gibiansky L; Ng CM; Gibiansky E
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38639818
[TBL] [Abstract][Full Text] [Related]
10. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
11. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
Gibiansky L; Gibiansky E
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
[TBL] [Abstract][Full Text] [Related]
12. Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.
Yamazaki S; Shen Z; Jiang Y; Smith BJ; Vicini P
Drug Metab Dispos; 2013 Jun; 41(6):1285-94. PubMed ID: 23557746
[TBL] [Abstract][Full Text] [Related]
13. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
[TBL] [Abstract][Full Text] [Related]
14. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
15. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
16. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations.
Byun JH; Jeon HS; Yun HY; Kim JK
PLoS Comput Biol; 2024 Apr; 20(4):e1012066. PubMed ID: 38656966
[TBL] [Abstract][Full Text] [Related]
17. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
Eudy RJ; Riggs MM; Gastonguay MR
AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
[TBL] [Abstract][Full Text] [Related]
18. Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.
Ma P
Pharm Res; 2012 Mar; 29(3):866-82. PubMed ID: 22130732
[TBL] [Abstract][Full Text] [Related]
19. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):17-26. PubMed ID: 28074395
[TBL] [Abstract][Full Text] [Related]
20. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]